{"nctId":"NCT02692716","briefTitle":"A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2017-01-17","type":"ACTUAL"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":3183,"armGroups":[{"label":"Oral semaglutide","type":"EXPERIMENTAL","interventionNames":["Drug: semaglutide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"semaglutide","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female diagnosed with type 2 diabetes\n* Age at least 50 years at screening and presence of cardiovascular disease, or age at least 60 years at screening and presence of at least one cardiovascular risk factor\n\nExclusion Criteria:\n\n* Current or previous (within 90 days prior to screening) treatment with any GLP-1 (glucagon-like peptide-1) receptor agonist, DPP-4 (dipeptidyl peptidase-4) inhibitor or pramlintide\n* Family or personal history of multiple endocrine neoplasia type 2 (MEN 2) or medullary thyroid carcinoma (MTC)\n* History of pancreatitis (acute or chronic)\n* History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery)\n* Subjects presently classified as being in New York Heart Association (NYHA) Class IV heart failure\n* Planned coronary, carotid or peripheral artery revascularisation known on the day of screening\n* Any of the following: myocardial infarction, stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 60 days prior to screening\n* Chronic or intermittent hemodialysis or peritoneal dialysis or severe renal impairment (corresponding to eGFR (glomerular filtration rate, estimated) below 30 mL/min/1.73 m\\^2)\n* History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ)","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke","description":"Number of participants experiencing a first event of a MACE, defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From Randomisation to First Occurrence of an Expanded Composite Cardiovascular Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke, UAP Requiring Hospitalisation or Hospitalisation for Heart Failure","description":"Participants experiencing first occurrence of an expanded composite CV endpoint \\[defined as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, UAP (unstable angina pectoris) requiring hospitalisation or heart failure requiring hospitalisation\\] are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From Randomisation to First Occurrence of Each of the Individual Components in the Expanded Composite Cardiovascular Endpoint","description":"Participants experiencing an event onset for each individual component of the expanded composite cardiovascular outcomes (defined as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, unstable angina requiring hospitalisation or heart failure requiring hospitalisation) are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From Randomisation to First Occurrence of a Composite Endpoint Consisting of: All-cause Death, Non-fatal Myocardial Infarction or Nonfatal Stroke","description":"Participants experiencing first occurrence of a composite CV endpoint (defined as all-cause death, non-fatal myocardial infarction or nonfatal stroke) are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From Randomisation to First Occurrence of Fatal or Non-fatal Myocardial Infarction","description":"Number of participants experiencing a first event of a fatal or non-fatal myocardial infarction are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From Randomisation to First Occurrence of Fatal or Non-fatal Stroke","description":"Number of participants experiencing a first event of a fatal or non-fatal stroke are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Time From Randomisation to All-cause Death","description":"Number of all-cause deaths in the study are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First AE Leading to Permanent Trial Product Discontinuation","description":"Number of participants who permanently discontinued trial product in ths study are presented. Results are based on the on-treatment observation period which starts at the date of first dose on trial product; ends on last date on trial product +38 days (ascertainment window).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"184","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Serious Adverse Events","description":"Number of serious adverse events were recorded from week 0 to week 87 in the study. Results are based on the on-treatment observation period which started at the date of first dose on trial product and ended on last date on trial product +38 days (ascertainment window).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"545","spread":null},{"groupId":"OG001","value":"618","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Eye Examination Category","description":"Participants with eye examination findings, normal, abnormal non clinically significant (NCS) and abnormal clinically significant (CS) at baseline (week -3) and end of treatment visit (week 83) are presented. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"848","spread":null},{"groupId":"OG001","value":"843","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"657","spread":null},{"groupId":"OG001","value":"673","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"845","spread":null},{"groupId":"OG001","value":"858","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"659","spread":null},{"groupId":"OG001","value":"661","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"783","spread":null},{"groupId":"OG001","value":"790","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"599","spread":null},{"groupId":"OG001","value":"597","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"780","spread":null},{"groupId":"OG001","value":"787","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"601","spread":null},{"groupId":"OG001","value":"599","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Pulse Rate","description":"Change from baseline (week 0) in pulse rate measured at the end of treatment visit (week 83) is reported. Results are based on the on-treatment observation period which started at the date of first dose on trial product, ended on last date on trial product +38 days (ascertainment window).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":"11"},{"groupId":"OG001","value":"-0","spread":"11"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic and Diastolic Blood Pressure","description":"Change from baseline (week 0) in systolic and diastolic blood pressure measured at the end of treatment visit (week 83) is reported. Results are based on the on-treatment observation period which started at the date of first dose on trial product, ended on last date on trial product +38 days (ascertainment window).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":"18"},{"groupId":"OG001","value":"-2","spread":"18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1","spread":"11"},{"groupId":"OG001","value":"-2","spread":"10"}]}]}]},{"type":"SECONDARY","title":"Change in Glycosylated Haemoglobin (HbA1c)","description":"Change from baseline (week 0) in HbA1c measured at the end of treatment visit (week 83) is reported. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.4"},{"groupId":"OG001","value":"-0.3","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change from baseline (week 0) in body weight measured at the end of treatment visit (week 83) is reported. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"5.7"},{"groupId":"OG001","value":"-0.8","spread":"4.5"}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol - Ratio to Baseline","description":"Change from baseline (week 0) in total cholesterol (mmol/L) at the end of treatment (week 83) visit is presented as ratio to baseline. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"21.9"},{"groupId":"OG001","value":"0.98","spread":"21.1"}]}]}]},{"type":"SECONDARY","title":"Change in LDL-cholesterol - Ratio to Baseline","description":"Change from baseline (week 0) in LDL cholesterol (mmol/L) at end of treatment visit (week 83) is presented as ratio to baseline. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"36.6"},{"groupId":"OG001","value":"0.97","spread":"34.5"}]}]}]},{"type":"SECONDARY","title":"Change in HDL-cholesterol - Ratio to Baseline","description":"Change from baseline (week 0) in HDL cholesterol (mmol/L) at end of treatment visit (week 83) is presented as ratio to baseline. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"16.9"},{"groupId":"OG001","value":"1.02","spread":"15.9"}]}]}]},{"type":"SECONDARY","title":"Change in Triglycerides - Ratio to Baseline","description":"Change from baseline (week 0) in triglycerides (mmol/L) at end of treatment visit (week 83) is presented as ratio to baseline. Results are based on the in-trial observation period which started at the date of randomisation, included the period after permanent trial product discontinuation, if any and ended at the date of the follow-up visit regardless of adherence to treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":"41.8"},{"groupId":"OG001","value":"0.97","spread":"39.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":301,"n":1591},"commonTop":[]}}}